Online inquiry

IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1781MR)

This product GTTS-WQ1781MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IL2RA gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000417.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3559
UniProt ID P01589
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ1781MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10080MR IVTScrip™ mRNA-Anti-FN, L19TNF(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA L19TNF
GTTS-WQ807MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-085
GTTS-WQ13249MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-05335810
GTTS-WQ7625MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN1029(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GEN1029
GTTS-WQ11176MR IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI0562
GTTS-WQ5843MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ14620MR IVTScrip™ mRNA-Anti-DLL3, SC0001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SC0001
GTTS-WQ5300MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CD166 AADC
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW